Loading clinical trials...
Loading clinical trials...
Background Preterm infants often need respiratory support. HFNV is a non-invasive method with benefits over CPAP, such as reduced nasal trauma and improved feeding. Aim Study the impact of low (2 LPM) vs. high (6 LPM) HFNV flow rates on CO2 levels in preterm infants. Methods Design: Prospective, crossover observational study. Participants: Preterm newborns (24-33.6 weeks' gestation) on HFNV. Procedure: Randomized flow rate adjustments, monitoring tcCO2 and other respiratory parameters over three hours. Outcomes Primary: Change in tcCO2. Secondary: Study terminations due to unsafe CO2 levels and changes in other respiratory metrics. Statistical Analysis Sample size: 45 infants. Analysis: Paired and unpaired t-tests for comparison within and between groups.
Background: Preterm Births: About 10% of births are preterm, with infants at risk for respiratory distress. Respiratory Support: Endotracheal ventilation has improved survival but increased the risk of bronchopulmonary dysplasia. Non-Invasive Support: Nasal CPAP minimizes complications. Heated, humidified high-flow nasal ventilation (HFNV) is an alternative, providing advantages like reduced nasal trauma and improved oral feeding. Aim: Primary Goal: Examine changes in transcutaneous CO2 (tcCO2) levels in preterm infants when using HFNV at low (2 LPM) versus high (6 LPM) flow rates. Hypothesis: Different HFNV flow rates will show minimal change in tcCO2 (≤5 mmHg). Methods: Design: Prospective, crossover observational study in Rambam NICU. Participants: Preterm newborns (24-33.6 weeks' gestation) needing HFNV. Inclusion Criteria: Stabilized HFNP settings and tcCO2, parental consent. Exclusion Criteria: Specific flow and CO2 levels, unstable conditions, or congenital malformations. Procedure: Randomize infants into two groups starting with 2 or 6 LPM flow rates, monitoring tcCO2 over three consecutive hours with alternating flow rates. Measurements: Primary Outcome: Change in tcCO2 levels. Secondary Outcomes: Number of study terminations due to pCO2/TcCO2 out of safety range, changes in respiratory parameters, and episodes of desaturation or bradycardia. Statistical Analysis: Sample Size: 45 infants needed to detect no difference with 90% power and 5% significance level. Data Analysis: Use paired and unpaired Student's t-tests to compare results within and between groups. Safety Protocol: The study will terminate if significant desaturation, bradycardia, or pCO2 levels outside the safety range occur.
Age
All ages
Sex
ALL
Healthy Volunteers
No
Rambam Medical Center
Haifa, Israel
Start Date
August 16, 2023
Primary Completion Date
December 1, 2026
Completion Date
December 31, 2026
Last Updated
November 28, 2025
45
ESTIMATED participants
change flow from 6 to 2 LPM. Follow TcCO2 for 3 hours
OTHER
change flow from 2 to 6 LPM. Follow TcCO2 for 3h
OTHER
Lead Sponsor
Rambam Health Care Campus
NCT06315556
NCT07450846
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions